Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02614508 · ClinicalTrials.gov registry record · Phase 1
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02614508 is a Phase 1 study that was terminated before completion, run by Emory University. The registered enrollment target is 1 participants.
The verdict
NCT02614508, a Phase 1 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of buparlisib when given together with ofatumumab or ibrutinib in treating patients with chronic lymphocytic leukemia that has returned after a period of improvement or does not respond to treatment. Buparlisib and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as ofatumumab, may block cancer growth in different ways by targeting certain cells. Giving buparlisib or ibrutinib and ofatumumab together may work better in treating patients with chronic lymphocytic leukemia.
Interventions
- DRUG Ibrutinib
- BIOLOGICAL Ofatumumab
- DRUG Buparlisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-01 |
| Est. Completion | 2019-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02614508
The ClinicalTrials.gov registry entry for NCT02614508 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ibrutinib is the first listed.
NCT02614508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02614508 about?
NCT02614508 is a clinical study titled "Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia". This phase I trial studies the side effects and best dose of buparlisib when given together with ofatumumab or ibrutinib in treating patients with chronic lymphocytic leukemia that has returned after a period of improvement or does not respond to treatment. Buparlisib and ibrutinib may stop the grow...
What is the current status of trial NCT02614508?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2016-01. Estimated completion is 2019-08.
What interventions are being tested in trial NCT02614508?
The interventions under investigation include: Ibrutinib (DRUG), Ofatumumab (BIOLOGICAL), Buparlisib (DRUG).
Who is sponsoring clinical trial NCT02614508?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.